Inspira™ Announces Business Plan Targets
Inspira Technologies OXY B.H.N. (Nasdaq: IINN) announced its business plan targets on June 20, 2024, focusing on the promotion of the INSPIRA™ ART100 following FDA clearance and the acceleration of the INSPIRA™ ART (Gen2).
The company aims to capture a share of the $19 billion mechanical ventilation market by 2030, with plans to deploy INSPIRA ART100 in multiple sites and countries. The first purchase order from the U.S. distributor has been received, with the first shipment scheduled for Q4 2024.
Key goals include the submission of the HYLA™ blood sensor for FDA clearance and ongoing development of the VORTX™ blood delivery system. The company believes the success of INSPIRA ART100 will pave the way for future breakthroughs with INSPIRA ART (Gen2).
- FDA clearance of INSPIRA™ ART100.
- First purchase order received from U.S. distributor.
- First shipment of INSPIRA™ ART100 scheduled for Q4 2024.
- Targeting a share of the $19 billion mechanical ventilation market by 2030.
- Ongoing development of INSPIRA™ ART (Gen2) technology.
- None listed.
INSPIRA™ ART (Gen 2) is a significant medical advancement, aiming to replace traditional mechanical ventilators by directly oxygenating blood without intubation. This has the potential to transform the $19 billion global mechanical ventilation market. One notable advantage here is patient comfort; being awake and avoiding intubation can reduce stress and complications.
The FDA clearance of INSPIRA™ ART100 provides a solid foundation for future developments. FDA clearance is a rigorous process, indicating a high level of confidence in the device's safety and efficacy. This clearance not only facilitates market entry but also boosts the company's credibility. The multi-site deployment suggests robust logistics and distribution planning, important for scaling operations and achieving market penetration.
The integration of the HYLA™ blood sensor into future devices is another promising development. This sensor could provide continuous monitoring and adjustments, improving patient outcomes by ensuring optimal oxygen levels are maintained. Phase 2 and Phase 3 R&D stages indicate significant progress, although they also come with certain risks—such as potential delays or unforeseen issues during testing.
For retail investors, these advancements suggest that Inspira is on a potential growth trajectory. However, it's essential to monitor the company's ability to meet its outlined targets and its success in subsequent FDA approvals and market deployments.
The announcement of plans to grab a share of the
However, investors should be cautious about the costs associated with R&D and multi-site deployments. These activities are capital intensive and can weigh on short-term profitability. The company’s ability to manage these costs while scaling operations will be critical for long-term success. The existing distribution agreements with Glo-Med Networks, Inc. also suggest a well-thought-out go-to-market strategy, reducing initial market entry risks.
In the short term, the stock might see a surge due to positive sentiment around the FDA clearance and first purchase order. Long-term value will depend on the successful commercialization of the next-gen INSPIRA™ ART (Gen 2) and continuous regulatory successes.
Company to aggressively promote INSPIRA™ ART100 in the
RA'ANANA,
![Inspira Technologies Logo Inspira Technologies Logo](https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg)
On the call, Inspira unveiled plans to build an opportunity for a share of the
Alongside the ongoing development of the INSPIRA ART (Gen 2) game-changing adaptive blood oxygenation technology, the Company is working on the multi-site deployment of the 510(k)
Key Highlights from the Presentation:
- The Company outlined the ground-breaking INSPIRA™ ART (Gen2) technology, with the aim of targeting a share of the projected
global mechanical ventilation market size estimated by 2030.$19 billion - Business goals for 2024-2025: Inspira is on track to submit its HYLA™ blood sensor, a key component of the INSPIRA™ ART (Gen 2) system, for FDA Clearance with Company plans to integrate the technology into the next generation of the INSPIRA™ ART100 device. In addition, Inspira is on track with phase 2 research and development for the VORTX™ blood delivery system and phase 3 verification and validation testing of the HYLA blood sensor.
- Inspira plans to deploy the INSPIRA™ ART100 in multiple sites and countries, and leverage it as a penetration model for the subsequent generation of its technology, the INSPIRA™ ART (Gen 2). We strongly believe that the INSPIRA™ ART100 research and development and regulatory success story is indicative of future potential breakthrough with INSPIRA™ ART (Gen 2)
About Inspira Technologies OXY B.H.N. LTD.
Inspira™ Technologies is an innovative medical technology company in the life support arena. The INSPIRA™ ART (Gen 2), also known as the INSPIRA™ ART500, shall include the Company's Adaptive Blood Oxygenation technology and is being designed to continuously measure the patient's blood parameters in real-time, delivering needed oxygen volume straight into the blood. By elevating patient oxygen saturation levels in minutes, this technology potentially allows patients to remain awake during treatment and therefore may enable patients to be treated in and beyond intensive care units, reducing the need for mechanical ventilation systems that require intubation and medically induced coma.
The Company received FDA 510(k) clearance for its INSPIRA ART100, a Cardiopulmonary Bypass System.
The Company's other products, including the INSPIRA ART (Gen 2) and HYLA™ blood sensor, have not been cleared or approved for marketing and sales by the US Food and Drug Administration (FDA) or any other regulatory authority.
For more information, please visit our corporate website: https://inspira-technologies.com
Forward-Looking Statements
This press release contains express or implied forward-looking statements pursuant to
For more details:
Public Relations Manager
Adi Shmueli
Inspira Technologies
info@inspirao2.com
+972-9-9664485
Copyright © 2018-2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved.
Logo: https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/inspira-announces-business-plan-targets-302178006.html
SOURCE Inspira Technologies
FAQ
What is Inspira Technologies' (IINN) recent business announcement about?
When is the first shipment of INSPIRA™ ART100 expected?
What is the market target for Inspira Technologies' INSPIRA™ ART (Gen2)?
What are the key components of INSPIRA™ ART (Gen2)?